Patents matching “adc”

US 12188005

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 7, 2025 · Expires Jan 2, 2045

US 12129476

Methods for measuring the potency of AADC viral vectors

VOYAGER THERAPEUTICS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

US 11976122

Anti-IL13Rα2 antibodies

ADC THERAPEUTICS SA · Granted May 7, 2024 · Expires May 2, 2044

US 11975056

AADC polynucleotides for the treatment of Parkinson's disease

VOYAGER THERAPEUTICS, INC. · Granted May 7, 2024 · Expires May 2, 2044

US 11938192

Dosage regimes for the administration of an anti-CD19 ADC

ADC THERAPEUTICS SA · Granted Mar 26, 2024 · Expires Mar 21, 2044

US 11813335

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA · Granted Nov 14, 2023 · Expires Nov 9, 2043

US 11759506

AADC polynucleotides for the treatment of Parkinson's disease

VOYAGER THERAPEUTICS, INC. · Granted Sep 19, 2023 · Expires Sep 14, 2043

US 11702473

Site-specific antibody-drug conjugates

ADC THERAPEUTICS SA · Granted Jul 18, 2023 · Expires Jul 13, 2043

US 11690918

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA · Granted Jul 4, 2023 · Expires Jun 29, 2043

US 11596696

Combination therapy with an anti-CD25 antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Mar 7, 2023 · Expires Mar 2, 2043

US 11426467

Dosage regimes for the administration of an anti-CD25 ADC

ADC THERAPEUTICS SA · Granted Aug 30, 2022 · Expires Aug 25, 2042

US 11384098

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA · Granted Jul 12, 2022 · Expires Jul 7, 2042

US 11318211

Dosage regimes for the administration of an anti-CD19 ADC

ADC THERAPEUTICS SA · Granted May 3, 2022 · Expires Apr 28, 2042

US 11160872

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA · Granted Nov 2, 2021 · Expires Oct 28, 2041

US 11084872

Method for treating breast cancer

ADC THERAPEUTICS SA · Granted Aug 10, 2021 · Expires Aug 5, 2041

US 11027000

AADC polynucleotides for the treatment of Parkinson's disease

VOYAGER THERAPEUTICS, INC. · Granted Jun 8, 2021 · Expires Jun 3, 2041

US 10898585

Gene therapy for AADC deficiency

PTC THERAPEUTICS, INC. · Granted Jan 26, 2021 · Expires Jan 21, 2041

US 10813952

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 27, 2020 · Expires Oct 22, 2040

US 10799596

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA · Granted Oct 13, 2020 · Expires Oct 8, 2040

US 10780096

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA · Granted Sep 22, 2020 · Expires Sep 17, 2040

US 10722594

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA · Granted Jul 28, 2020 · Expires Jul 23, 2040

US 10597450

Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

ADC THERAPEUTICS SA · Granted Mar 24, 2020 · Expires Mar 19, 2040

US 10544223

Combination therapy with an anti-axl antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Jan 28, 2020 · Expires Jan 23, 2040

US 10335466

AADC polynucleotides for the treatment of parkinson's disease

VOYAGER THERAPEUTICS, INC. · Granted Jul 2, 2019 · Expires Jun 27, 2039